Eohilia denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for eohilia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues a Duplicate-Therapy Denial for Eohilia in Eosinophilic Esophagitis

Eohilia (budesonide oral suspension) is an FDA-approved swallowed topical corticosteroid indicated for eosinophilic esophagitis (EoE). A duplicate-therapy denial from Aetna typically occurs when another swallowed corticosteroid preparation — most commonly a compounded budesonide slurry or fluticasone — is already active on the pharmacy record. Aetna's clinical policy may classify these as therapeutically equivalent, triggering an automatic duplicate flag. However, Eohilia is the only FDA-approved product in its class specifically formulated and studied for EoE; compounded alternatives lack that regulatory approval and standardized formulation. That clinical distinction is the foundation of the appeal.

## Why This Denial Is Appealable

A duplicate-therapy determination is made by claims software comparing drug classes, not by a clinician reviewing the patient's individual chart and treatment history. Under ACA §2719, non-grandfathered plans must provide internal appeal and independent external review for coverage denials. Under ERISA §503, employer-sponsored plans must offer a full-and-fair review with written explanation. You generally have 180 days from the denial notice to file an internal appeal. External review must typically be initiated within 4 months of a final internal denial. An expedited review path (72-hour decision) is available when the patient's condition is urgent.

## Concrete Appeal Steps

1. Identify the alleged duplicate: The denial letter or EOB should name the drug Aetna considers equivalent. Confirm whether it is currently active or has already been discontinued. 2. If the prior agent is discontinued: Provide pharmacy records showing the last dispense date, demonstrating there is no active duplication. 3. If the prior agent is active: Submit a medical-necessity argument explaining why Eohilia is clinically distinct and not duplicative — specifically the FDA-approval status and formulation specificity. 4. File the internal appeal with supporting documentation. 5. Escalate to external review if the internal appeal is upheld.

## Documentation to Gather

• EoE diagnosis: gastroenterology records, endoscopy reports with biopsy confirming eosinophilic esophagitis.
• Prior swallowed corticosteroid history: pharmacy records and clinical notes documenting the prior agent, dates of use, response (symptomatic and endoscopic), and reason for transition to Eohilia.
• Prescriber medical-necessity letter: the treating gastroenterologist should explain why Eohilia is not therapeutically equivalent to the prior agent for this patient — including the FDA-approved, purpose-designed formulation — and why switching is not appropriate.
• FDA label for Eohilia: documents the approved indication for EoE and the product's distinct formulation, distinguishing it from compounded alternatives.

## Criteria-Mapping Structure

| Aetna Policy Criterion | Supporting Evidence | |---|---| | Prior agent is no longer active (no true duplication) | Pharmacy record showing last dispense / discontinuation date | | Clinical distinction from formulary alternative | Prescriber letter + FDA label confirming Eohilia's unique approved formulation | | Patient history supports transition | Chart notes documenting prior therapy response and clinical rationale for change |

Consult Aetna's published clinical policy for eosinophilic esophagitis treatments and the FDA-approved prescribing information for Eohilia to identify every criterion your documentation must address.